Keyphrases
Adverse Events
16%
Antidiabetic Agents
66%
Antineoplastic Agents
16%
Clinical Database
33%
Confidence Interval
16%
Diabetes
16%
Diabetic
16%
Diabetic Patients
16%
Effects on Survival
16%
Favorable Outcome
16%
Hazard Ratio
16%
International Metastatic Renal Cell Carcinoma Database Consortium
16%
Metastatic RCC
66%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Metformin
100%
Metformin Use
100%
Objective Response Rate
16%
Overall Survival
66%
Phase II Clinical Trial
16%
Phase III Clinical Trial
16%
Progression-free Survival
16%
Renal Cell Carcinoma
16%
Retrospective Analysis
16%
Subgroup Analysis
16%
Sunitinib
50%
Survival Benefit
50%
Survival Outcomes
100%
Therapy Types
16%
Tyrosine Kinase Inhibitor
16%
Vascular Endothelial Growth Factor
16%
Without Diabetes
16%
Medicine and Dentistry
Adverse Event
8%
Anticarcinogen
8%
Antidiabetic Agent
33%
Clear Cell Renal Cell Carcinoma
8%
Clinical Trial
25%
Diabetes
16%
Diabetes Mellitus
8%
Glycon
100%
Hazard Ratio
8%
High Risk Population
16%
Kidney Metastasis
100%
Malignant Neoplasm
8%
Observational Study
8%
Overall Survival
33%
Progression Free Survival
8%
Subgroup Analysis
8%
Sunitinib
25%
Tyrosine-Kinase Inhibitor
8%
Vasculotropin
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Anticarcinogen
8%
Antidiabetic Agent
33%
Clinical Study
8%
Clinical Trial
25%
Diabetes Mellitus
8%
Kidney Metastasis
100%
Malignant Neoplasm
8%
Metformin
100%
Observational Study
8%
Overall Survival
33%
Preclinical Study
8%
Progression Free Survival
8%
Protein Tyrosine Kinase Inhibitor
8%
Renal Cell Carcinoma
8%
Sunitinib
25%
Vasculotropin
8%